Biomarker-Driven Phase 2 Study of Nivolumab in Advanced Metastatic NSCLC
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 22 May 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 17 May 2019 Status changed to withdrawn prior to enrolment.
- 31 Aug 2018 Biomarkers information updated
- 11 Aug 2017 Planned End Date changed from 1 Oct 2022 to 1 Jul 2022.